Company Monitoring Page for Eli-Lilly

latest headlines for company on cafepharma

US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
Reuters
Sun, 12/3/23 - 09:29 pm
Tags:
Eli Lilly, Zepbound, Novo Nordisk, Wegovy
Lilly Puts Potential $660M on the Line for Protein-Protein Interaction Blockers
BioSpace
Wed, 11/29/23 - 11:49 am
Tags:
Eli Lilly, PRISM BioLab, small molecule inhibitors
Teva drops patent case against Lilly after two Ajovy patents deemed invalid
Fierce Pharma
Tue, 11/28/23 - 11:40 pm
Tags:
Teva Pharmaceutical, legal, Eli Lilly, Ajovy, patents, migraines
Eli Lilly supports Alto Neuroscience in $45m Series C round
Clinical Trials Arena
Wed, 11/22/23 - 11:30 am
Tags:
Eli Lilly, Alto Neuroscience, funding, psychiatric diesase
The Next Generation of Weight Loss Drugs is Rapidly Approaching
BioSpace
Mon, 11/20/23 - 11:32 am
Tags:
weightloss, Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Wegovy, Zepbound
Manufacturer Lonza says it will not fill obesity drug syringes
Reuters
Fri, 11/17/23 - 10:02 am
Tags:
Lonza, drug manufacturing, obesity, Novo Nordisk, Eli Lilly
Why Eli Lilly Stock Flopped While the Market Popped Today
Motley Fool
Wed, 11/15/23 - 11:47 pm
Tags:
Eli Lilly, Europe, drug manufacturing
Novo Nordisk fights back at Lilly with Wegovy combo trial against Zepbound in obesity
https://bit.ly/49zNkYL
Wed, 11/15/23 - 12:04 pm
Tags:
Novo Nordisk, Eli Lilly, clinical trials, CagriSema, Wegovy, Zepbound, obesity
Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines
BioSpace
Mon, 11/13/23 - 11:58 am
Tags:
ViaNautis Bio, Eli Lilly, genetic nanomedicine, UCB Pharma, funding
AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year
Pharmaphorum
Mon, 11/13/23 - 10:03 am
Tags:
Eli Lilly, AHA, siRNA, lipoprotein(a), cardiovascular disease, lepodisiran
Lilly’s Zepbound vs. Novo’s Wegovy: The Weight-Loss Drug Race Has Officially Started
Motley Fool
Sun, 11/12/23 - 09:21 pm
Tags:
Eli Lilly, Zepbound, Novo Nordisk, Wegovy, weightloss
Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.
Motley Fool
Fri, 11/10/23 - 12:19 pm
Tags:
Eli Lilly, donanemab, tirzepatide, mirikizumab, lebrikizumab, pirtobrutinib
How Eli Lilly’s obesity drug Zepbound is poised to reshape pharma markets
Medical Marketing and Media
Thu, 11/9/23 - 11:41 pm
Tags:
Eli Lilly, tirzepatide, weightloss, Zepbound, Mounjaro
FDA Approves Eli Lilly’s Zepbound for Chronic Weight Management
BioSpace
Wed, 11/8/23 - 10:05 pm
Tags:
Eli Lilly, Zepbound, FDA, weightloss
An obesity drug biotech gets buy-in from Eli Lilly, venture firms
BioPharma Dive
Tue, 11/7/23 - 09:50 am
Tags:
OrsoBio, Eli Lilly, funding, obesity, diabetes
Novo, Lilly Weight-Loss Drug Juggernaut Has Nowhere to Go But Up
BioSpace
Sun, 11/5/23 - 11:12 pm
Tags:
Novo Nordisk, Eli Lilly, Wegovy, Mounjaro, weightlosss
Eli Lilly Just Added Another Potential Billion-Dollar Product
Motley Fool
Sun, 11/5/23 - 11:08 pm
Tags:
Eli Lilly, ulcerative colitis, Omvoh
Lilly's blockbuster Mounjaro boosts third quarter results, supply issues persist
Reuters
Thu, 11/2/23 - 11:44 am
Tags:
Eli Lilly, earnings, Mounjaro
Eli Lilly, Redwire head to space to explore next frontier of drug development
Fierce Pharma
Tue, 10/31/23 - 10:08 am
Tags:
Eli Lilly, drug development, Redwire, PIL-BOX, in-space manufacturing
Lilly buys Beam’s option on Verve drug programs
Pharmaforum
Tue, 10/31/23 - 10:06 am
Tags:
Eli Lilly, gene editing, Beam Therapeutics, Verve Therapeutics

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.